Overview

Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Status:
Completed
Trial end date:
2016-05-18
Target enrollment:
Participant gender:
Summary
This Phase 1 trial will assess the dose-related safety and PK profile of different doses of NVR 3-778, first in healthy volunteer subjects (part I) and subsequently in patients with chronic hepatitis B (part II). Additionally, in Part II, changes in patients' serum HBV DNA levels and other virologic efficacy parameters will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Novira Therapeutics, Inc.
Treatments:
Interferon-alpha
Peginterferon alfa-2a